COMMUNIQUÉS West-GlobeNewswire

Aro Biotherapeutics Appoints Biotechnology Executive Brett Blackman, Ph.D., to its Board of Directors
29/09/2026
PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aro Biotherapeutics, a clinical-stage biotechnology company developing targeted short-interfering RNA (siRNA) medicines for the treatment of diseases with high unmet [...]
RESTEM to Present at the 2026 Cell & Gene Meeting on the Mesa
29/09/2026
MIAMI, Sept. 29, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that Chief [...]
Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting
29/09/2026
Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting Halle (Saale) / Munich, Germany, September 29 , 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a [...]
Regulated information: Disclosure of a transparency notification from BlackRock, Inc.
29/09/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 29 September 2026 – 6 PM CET Disclosure of a transparency notification from BlackRock, Inc. Pursuant to the Belgian act of 2 May 2007 on the [...]
Portsmouth Square, Inc. Reports Fiscal 2026 Results; Hotel Revenue Increases 20% Year-Over-Year and Operating Performance Strengthens as San Francisco Recovery Progresses
29/09/2026
Los Angeles, California, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Portsmouth Square, Inc. (the "Company" or "Portsmouth") financial results for the fiscal year ended June 30, 2026. Portsmouth operates in two reportable [...]
DiFusion to Define Therapeutic Biomaterials Category at NASS 2026
29/09/2026
Red Theater presentation will distinguish conventional biotolerable implants from materials deliberately engineered to influence the host response and participate in healing AUSTIN, Texas, Sept. 29, 2026 (GLOBE NEWSWIRE [...]
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
29/09/2026
- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood- [...]
Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality
29/09/2026
Patients reported high satisfaction and visible improvements in skin elasticity, youthfulness, and radiance CLEARWATER, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or [...]
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
29/09/2026
Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data Topline results expected in the first [...]
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
29/09/2026
Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026 TEL AVIV, Israel, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a [...]
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
29/09/2026
NEW YORK and WALTHAM, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]
Noah Medical’s Galaxy System Enters Commercial Use in Asia with First Procedure Completed in Hong Kong
29/09/2026
SAN JOSE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Medical robotics innovator Noah Medical today announced the successful completion of its first commercial procedure in Asia using the Galaxy™ System at Prince of [...]
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
29/09/2026
LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a [...]
Silexion Therapeutics Announces Exercise of Warrants
29/09/2026
Cayman Islands, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS- [...]
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
29/09/2026
More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 48 42% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing from 23.7% over [...]
J-Star Holding Co., Ltd. Chairman and CEO Jonathan Chiang to Relocate to the United States to Lead Growth Initiatives
29/09/2026
TAIPEI, Taiwan, Sept. 29, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) ("J-Star" or the "Company"), a global manufacturer of carbon fiber and composite material products, today announced that [...]
TOMI Environmental Solutions Targets Next Phase of Growth in the Scaling Robotaxi, Drone and Robotics Economy
29/09/2026
TOMI's iHP Platform Concept Extends Core Technology into Robotaxi Depots, Drone Fleets and Robotic Systems FREDERICK, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ [...]
Celularity Announces Naveen Jain to Join Board of Directors
29/09/2026
Viome founder and CEO brings a consumer-focused vision for bringing regenerative therapies to more people and advancing proactive health FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: [...]
Lite Strategy Reports Fiscal Year 2026 Financial Results
29/09/2026
SAN DIEGO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury reserve asset announced [...]

Pages